Mouse only (CD18HYP/CD18KO disease models, recipient mice, NSG mice); no large-animal tox
“The applicant also used surrogate Lin- HSPCs transduced with the Chim-CD18-WPRE LV transplanted into recipient mice for their definitive in vivo toxicology and BD studies.”
✓ VerifiedFDA pharmacology/toxicology review, p. 8Source ↗
“CD18HYP and CD18KO mice have deficient CD18 expression and impaired neutrophil migration and inflammatory responses similar to LAD-I patients.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Surrogate molecule
Yes: murine Lin- HSPCs transduced with clinical vector; healthy-donor human CD34+ cells in NSG mice
“The final clinical product and source material was not used in the nonclinical studies summarized in this memo due to feasibility issues obtaining sufficient CD34+ HSCs from LAD-I patients.”
✓ VerifiedFDA pharmacology/toxicology review, p. 8Source ↗
Species: general tox
Mouse only (recipient mice transplanted with transduced murine Lin- HSPCs)
“The applicant also used surrogate Lin- HSPCs transduced with the Chim-CD18-WPRE LV transplanted into recipient mice for their definitive in vivo toxicology and BD studies.”
✓ VerifiedFDA pharmacology/toxicology review, p. 8Source ↗
Species: DART
Not conducted (product type; reproductive-tissue biodistribution near background)
“Studies were not conducted to evaluate this developmental and reproductive toxicity based on the product type and due to the lack of concerning findings in reproductive tissues in Study #7 (study report no. NSR-7).”
✓ VerifiedFDA pharmacology/toxicology review, p. 25Source ↗
Species: carcinogenicity
Not conducted (traditional studies not suitable for this product type)
“Traditional carcinogenicity studies were not conducted since they are not suitable for assessment of this drug product type.”
✓ VerifiedFDA pharmacology/toxicology review, p. 26Source ↗
Surrogate used in
Yes: CD18HYP/CD18KO mouse Lin- HSPCs transduced with the clinical vector for in vivo pharmacology
“The applicant also used surrogate Lin- HSPCs from CD18HYP and CD18KO mice transduced with the clinical vector to demonstrate donor cell engraftment and improved neutrophil extravasation to tissue-specific sites of inflammation for the in vivo pharmacology studies.”
✓ VerifiedFDA pharmacology/toxicology review, p. 8Source ↗